Bioequivalence and Bioavailability Forum

s2wR != mse, FDA != EMA [General Sta­tis­tics]

posted by ElMaestro  – Denmark, 2017-03-04 20:13 (3403 d 14:10 ago) – Posting: # 17133
Views: 23,940

I like that post, d_labes ,

❝ But s2wR = MSE is not necessarily true in all cases, although it is in many cases a reasonable assumption.

...and accordingly when the optimizer fails, plugging in the GLM residual (expressed as MSE) as a new starter value for s2wR (and even S2wT where applicable) may be a very decent last-ditch attempt.

❝ Moreover the FDA evaluation uses intra-subject constrasts to evaluate s2wR

What does this mean? Don't you usually get it from the REML covarance matrix?

I think EMA's approach can be condensed into intra-Subject contrasts to derive S2wR from completers.

Complete thread:

• Confidence Interval for Transformed data Unbalanced study usfda_emea 2007-03-06 14:39 
  • CI for Transformed data Unbalanced study Helmut 2007-03-06 16:46
    • CI for Transformed data Unbalanced study drshiv 2007-03-06 18:49
    • CI for Transformed data Unbalanced study usfda_emea 2007-03-07 06:21
      • CI for Transformed data Unbalanced study Helmut 2007-03-07 12:04
        • CI for Transformed data Unbalanced study usfda_emea 2007-03-07 12:34
        • CI for Transformed data Unbalanced study Ohlbe 2014-07-30 15:04
          • LSM limbo Helmut 2014-07-31 02:54
            • LSM limbo Ohlbe 2014-07-31 09:47
            • 90% CI limbo VStus 2017-03-01 14:07
              • RSABE ⇒ ABEL Helmut 2017-03-03 13:34
                • RSABE ⇒ ABEL VStus 2017-03-03 15:31
                  • s2wR != mse, FDA != EMA d_labes 2017-03-04 14:49
                    • s2wR != mse, FDA != EMAElMaestro 2017-03-04 19:13
                      • s2wR from ISC in FDA approach d_labes 2017-03-05 12:18
                        • s2wR from ISC in FDA approach ElMaestro 2017-03-05 13:50
                    • s2wR != mse, FDA != EMA VStus 2017-03-04 21:41
                      • s2wR != mse, FDA != EMA Helmut 2017-03-06 13:40